EsoCap Technology
IP and Data Protection
Several worldwide patents owned by EsoCap have been filed.
EsoCap has filed a total of eight patents. The first patent is already granted in key geographies:
USA
EU
Japan
Australia
Brazil
Canada
India
Israel
South Korea
Mexico
New Zealand
Russia
South Africa
and expected in further strategic countries.
Ring-fencing patent applications covering specific aspects of the technology such as the capsule holder and production methods have been granted in the EU and in Japan while the national roll-out is ongoing in further countries . Two additional patent applications have been filed regarding the manufacturing process. More recently 3 patent applications have been filed regarding the application of the EsoCap platform in several diseases of the esophagus.
Orphan Drug Designation (ODD)
EsoCap AG has received Orphan Drug Designation (ODD) from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE. The FDA has recognized ESO-101’s potential to offer a significant therapeutic benefit for patients suffering from EoE. Orphan Drug Designation provides a sponsor with certain benefits and incentives, including a period of marketing exclusivity when regulatory approval is obtained for the designated indication. A similar application has been submitted in Europe.
